Variant Bio is leveraging cutting-edge genomics and computational biology to discover and develop novel therapeutics for rare diseases. Their unique approach leverages the power of genomics to identify individuals with exceptional health traits and uncover the underlying genetic mechanisms responsible for these traits. Combining various types of biological data to identify causal genes and establish disease mechanisms. Their proprietary, VB-Inference platform, uses advanced analytics to infer causal relationships from complex genetic data. Variant Bio's reliance on multi-omic data and advanced analytics provides a robust foundation for drug discovery. Variant Bio has a pipeline of drug candidates targeting various diseases, including rare genetic disorders and neurodegenerative conditions.

<p>Variant Bio is using genetic differences to identify therapies to improve health. The human population has a variety of exceptional traits. This ranges from diabetes protection, low cholesterol, Cholera resistance to strong bones. Variant Bio is pioneering people-driven therapeutics that uses human diversity to identify the basis of disease and resistance to it. This requires studying the genomes of people with exceptional health-related traits that can inspire new therapies to lower cholesterol and treat osteoporosis, for example. Variant Bio is using innovative whole-genome sequencing and custom algorithms that can identify novel and population-specific genetic variants to go from genomes to targets.</p>


Variant Bio

Founded: 2018
Location: Seattle, WA
Employee range: 11 - 50
Funding: 100-500M

About:

Jobs: